A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.

Study Overview

• Status: Terminated
• Conditions: Acute Myeloid Leukemia
• Intervention / Treatment: Drug: ASTX660; Drug: ASTX727

Detailed Description

This is a three-part dose escalation and dose expansion Phase 1 study of ASTX660 alone and in combination with ASTX727 in adults with R/R AML.

Part 1 is an open-label, single arm, dose escalation with ASTX660 in combination with ASTX727 at the standard fixed dose combination (FDC).

Part 2 is an open-label, randomized, dose escalation intended to evaluate ASTX660 as a monotherapy and ASTX660 in combination with ASTX727 FDC.

Part 3 is an exploratory single arm dose expansion to further expand the number of participants treated with ASTX660 in combination with ASTX727 FDC.

• Study Type: Interventional
• Enrollment (Actual): 68
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94143
      • University of California San Francisco
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Smilow Cancer Hospital
  • Florida
    • Miami, Florida, United States, 33136
      • Sylvester Comprehensive Cancer Center
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Northside Hospital - The Blood and Marrow Transplant Group of Georgia
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medical Center
  • Indiana
    • Indianapolis, Indiana, United States, 46237
      • Franciscan Health Indianapolis (Blood and Marrow Transplantation)
  • Kansas
    • Fairway, Kansas, United States, 66205
      • The University of Kansas Clinical Research Center
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic
  • New York
    • Buffalo, New York, United States, 14263
      • Roswell Park Comprehensive Cancer Center
    • New York, New York, United States, 10029
      • Mount Sinai Medical Center
    • New York, New York, United States, 10016
      • New York University Langone Health
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Lineberger Comprehensive Cancer Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University Comprehensive Cancer Center
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt - Ingram Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Have a projected life expectancy of at least 12 weeks, as assessed by the Investigator.

2. Have histological confirmation of AML by World Health Organization (WHO) 2016 criteria and are either:

   1. refractory to intensive induction chemotherapy OR
   2. relapsed after intensive induction chemotherapy or stem cell transplant OR
   3. relapsed after or refractory to treatment with molecularly targeted and/or low-intensity chemotherapeutic regimens.
3. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
4. Have adequate renal function as demonstrated by measured or calculated creatinine clearance ≥60 mL/min.

5. Have adequate liver function as demonstrated by:

   1. Aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN)
   2. Alanine aminotransferase (ALT) ≤2.5 × ULN
   3. Bilirubin ≤1.5 × ULN - unless considered due to leukemic organ involvement.
6. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.

Exclusion Criteria:

1. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.
2. Known clinically active central nervous system (CNS) leukemia.
3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
4. Diagnosis of acute promyelocytic leukemia (M3 AML or APML).
5. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
6. Graft Versus Host Disease (GVHD), or any GVHD requiring treatment with immunosuppression. Any GVHD treatment (including calcineurin inhibitors) must be discontinued at least 28 days prior to Day 1 of study treatment.
7. Presence of persistent toxicities of Grade >1 from prior treatment including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, and surgery (except for alopecia).
8. Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients.
9. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
10. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety, or the integrity of study outcomes, or interfere with the absorption or metabolism of ASTX660 or ASTX727.
11. History of, or at risk for, cardiac disease.
12. Known human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (participants with laboratory evidence of no active replication will be permitted).
13. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the participant to high risk of noncompliance with the protocol treatment or assessments.
14. Treated with any investigational therapy within 2 weeks of the first dose of study treatment or treatment with a myelosuppressive therapy within 4 weeks of the first dose of study treatment.
15. In Parts 1 and 2, prior treatment with decitabine for more than 2 cycles. In Part 3, any treatment with an HMA (azacitidine or decitabine, for more than one cycle).
16. Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to ASTX660-02 (Note: G-tube administration is not allowed).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1; ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)	Drug: ASTX660; Capsule for oral administration; Drug: ASTX727; Tablet for oral administration; Other Names: cedazuridine + decitabine
Experimental: Part 2; ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)	Drug: ASTX660; Capsule for oral administration; Drug: ASTX727; Tablet for oral administration; Other Names: cedazuridine + decitabine
Experimental: Part 3; ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)	Drug: ASTX660; Capsule for oral administration; Drug: ASTX727; Tablet for oral administration; Other Names: cedazuridine + decitabine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety Assessment: Number of participants with treatment-emergent adverse events (TEAEs)	Up to 30 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Response rate: Number of participants achieving complete response (CR), complete response with incomplete hematological recovery (CRi), and partial response (PR) as determined by the European LeukemiaNet (ELN) 2017 response criteria for AML	Up to 30 months
Time to response: Time from first dose to the first documented evidence of response	Up to 30 months
Duration of response: Time from the start of response until disease progression or relapse	Up to 30 months
Overall survival: Time since first dose until death due to any cause	Up to 30 months
Composite complete response: Number of participants (sum of CR+CRi)	Up to 30 months
Complete response with partial hematological recovery (CRh): Number of participants	Up to Month 30
Pharmacokinetic parameter: Area under the curve (AUC)	On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
Pharmacokinetic parameter: Maximum plasma concentration (Cmax)	On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
Pharmacokinetic parameter: Minimum plasma concentration (Cmin)	On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax)	On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
Pharmacokinetic parameter: Half-life (t½)	On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)

Collaborators and Investigators

• Sponsor: Astex Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2020
• Primary Completion (Actual): January 14, 2022
• Study Completion (Actual): January 14, 2022

Study Registration Dates

• First Submitted: November 5, 2019
• First Submitted That Met QC Criteria: November 5, 2019
• First Posted (Actual): November 7, 2019

Study Record Updates

• Last Update Posted (Estimate): February 20, 2023
• Last Update Submitted That Met QC Criteria: February 16, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: AML; Decitabine; MDS; Bone marrow; Myelodysplastic syndrome; Acute myeloid leukemia; CMML; Chronic myelomonocytic leukemia; ASTX727; Cedazuridine; ASTX660; cIAP1; Cellular inhibitor of apoptosis protein; XIAP; CDAi; Cytidine deaminase inhibitor
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Decitabine
• Other Study ID Numbers: ASTX660-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No